Gyre Therapeutics (GYRE) Other Non-Current Assets (2011 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Other Non-Current Assets of $4.9 million for Q1 2026, down 11.05% year-over-year from $5.6 million in Q1 2025, and down 2.1% quarter-over-quarter from $5.0 million in Q4 2025.
Gyre Therapeutics (GYRE) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Other Non-Current Assets for 16 consecutive years, with $4.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 11.05% year-over-year to $4.9 million; the TTM figure through Mar 2026 stood at $4.9 million (down 11.05% YoY), while the FY2025 annual figure was $5.0 million, up 66.6% from the prior year.
- Other Non-Current Assets eased to $4.9 million in Q1 2026 per GYRE's latest filing, from $5.0 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $5.6 million in Q1 2025 and bottomed at $168000.0 in Q2 2022.
- Historically, Other Non-Current Assets has averaged $2.3 million across 5 years, with a median of $1.3 million in 2024.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets sank 85.63% — and 2024, when it surged 1546.43%.
- Gyre Therapeutics' Other Non-Current Assets stood at $3.4 million in 2022, then tumbled by 70.68% to $995000.0 in 2023, then soared by 204.52% to $3.0 million in 2024, then soared by 66.6% to $5.0 million in 2025, then decreased by 2.1% to $4.9 million in 2026.
- Business Quant data shows GYRE's Other Non-Current Assets at $4.9 million in Q1 2026, $5.0 million in Q4 2025, and $5.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 7.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.34 Mn |
| Mar 31, 2026 | 4.94 Mn |
| Dec 31, 2025 | 5.05 Mn |
| Sep 30, 2025 | 5.32 Mn |
| Jun 30, 2025 | 5.34 Mn |
| Mar 31, 2025 | 5.56 Mn |
| Dec 31, 2024 | 3.03 Mn |
| Sep 30, 2024 | 2.77 Mn |
| Jun 30, 2024 | 1.28 Mn |
| Mar 31, 2024 | 802,000.00 |
| Dec 31, 2023 | 995,000.00 |
| Sep 30, 2023 | 168,000.00 |
| Jun 30, 2023 | 168,000.00 |
| Mar 31, 2023 | 168,000.00 |
| Dec 31, 2022 | 3.39 Mn |
| Sep 30, 2022 | 168,000.00 |
| Jun 30, 2022 | 168,000.00 |
| Mar 31, 2022 | 472,000.00 |
| Dec 31, 2021 | 472,000.00 |
| Sep 30, 2021 | 869,000.00 |